Varaico: Literature-Extracted Genetic Variants

Gene:CFTR
Variant:p.R352W
Back to variants list

CFTR

NM_000492.4:p.R352W

Associated Papers

Prevalence, type, and clinical implications of CFTR variants in bronchiectasis.

Gramegna A et al.

Pulmonology, 2026

General trends in the calnexin-dependent expression and pharmacological rescue of clinical CFTR variants.

Tedman A et al.

Elife, 2025

41379933 (PubMed )
Supplement: elife-107180-supp1.xlsx › CANX_KO_Counts

Cystic fibrosis risk variants confer protection against inflammatory bowel disease.

Yu M et al.

Cell Genomics, 2025

41330381 (PubMed )
Supplement: mmc3.xlsx › Sheet1

In silico, in vitro and ex vivo characterization of cystic fibrosis transmembrane conductance regulator pathogenic variants localized in the fourth intracellular loop and their rescue by modulators.

Pesce E et al.

British Journal of Pharmacology, 2025

Successful Desensitisation With Cystic Fibrosis Transmembrane Conductance Regulator Modulatory Drugs in Delayed Cutaneous Hypersensitivity Reactions.

Kazancioglu A et al.

Journal of Paediatrics and Child Health, 2025

Efficacy of elexacaftor/tezacaftor/ivacaftor in non-cystic fibrosis bronchiectasis patients with a single pathogenic CFTR mutation: a retrospective cohort analysis.

Papadakis L et al.

Erj Open Research, 2025

41189580 (PubMed )
Supplement: 00007-2025.SUPPLEMENT.pdf

General Trends in the Calnexin-Dependent Expression and Pharmacological Rescue of Clinical CFTR Variants.

Tedman A et al.

Biorxiv : the Preprint Server for Biology, 2025

40964320 (PubMed )
Supplement: media-1.pdf

Identification and Characterization of a Rare Exon 22 Duplication in CFTR in Two Families.

Ahting S et al.

International Journal of Molecular Sciences, 2025

40429633 (PubMed )
Supplement: ijms-26-04487-s001.zip › CFTR2_25September2024.xlsx › CFTR2_variants__genomic_info

Clinical and genetic profiles of paediatric patients with cystic fibrosis from Western India.

Chandane P et al.

Lung India : Official Organ of Indian Chest Society, 2025

Comprehensive pharmacogenomics profiling of the Serbian population.

Jelovac M et al.

Frontiers in Pharmacology, 2025

40166472 (PubMed )
Supplement: DataSheet1.xlsx › 5._PharmCAT_diffrences

Cystic fibrosis risk variants confer protection against inflammatory bowel disease.

Yu M et al.

Medrxiv : the Preprint Server for Health Sciences, 2024

39677473 (PubMed )
Supplement: media-1.xlsx › ST3

Impact of the expanded label for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del variant in the USA.

Cromwell EA et al.

The European Respiratory Journal, 2024

39227072 (PubMed )
Supplement: ERJ-01146-2024.Supplement.pdf

Diversity of CFTR variants across ancestries characterized using 454,727 UK biobank whole exome sequences.

Ideozu JE et al.

Genome Medicine, 2024

Benchmarking AlphaMissense Pathogenicity Predictions Against Cystic Fibrosis Variants.

McDonald EF et al.

Biorxiv : the Preprint Server for Biology, 2024

37873426 (PubMed )
Supplement: media-2.xlsx › Sheet1

Benchmarking AlphaMissense pathogenicity predictions against cystic fibrosis variants.

McDonald EF et al.

Plos One, 2024

38271453 (PubMed )
Supplement: pone.0297560.s008.xlsx › Sheet1

Clinical and genetic features of cystic fibrosis in Japan.

Kozawa Y et al.

Journal of Human Genetics, 2023

Cystic Fibrosis Screen Positive, Inconclusive Diagnosis Genotypes in People with Cystic Fibrosis from the U.S. Patient Registry.

Salinas DB et al.

Annals of the American Thoracic Society, 2023

Rescue of Rare CFTR Trafficking Mutants Highlights a Structural Location-Dependent Pattern for Correction.

Zacarias S et al.

International Journal of Molecular Sciences, 2023

36834620 (PubMed )
Supplement: ijms-24-03211-s001.zip › ijms-2071953-supplementary.pdf

Organoid Technology and Its Role for Theratyping Applications in Cystic Fibrosis.

Conti J et al.

Children (basel, Switzerland), 2022

Elexacaftor/tezacaftor/ivacaftor for CFTR variants giving rise to diagnostic uncertainty: Personalised medicine or over-medicalisation?

Salvatore D et al.

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society, 2022

A historical overview of advances in molecular genetic/genomic studies of the ABO blood group system.

Yamamoto F

Glycoconjugate Journal, 2022

Systematic estimation of cystic fibrosis prevalence in Chinese and genetic spectrum comparison to Caucasians.

Ni Q et al.

Orphanet Journal of Rare Diseases, 2022

35313924 (PubMed )
Supplement: 13023_2022_2279_MOESM1_ESM.xls › TableS1_CFTR_sites

Discovery of CFTR modulators for the treatment of cystic fibrosis.

Lopes-Pacheco M et al.

Expert Opinion on Drug Discovery, 2021

Structural Biology Helps Interpret Variants of Uncertain Significance in Genes Causing Endocrine and Metabolic Disorders.

Ittisoponpisan S et al.

Journal of the Endocrine Society, 2018

30019023 (PubMed )
Supplement: js.2018-00077.sd2.xls › Sheet1

Mutations in SELENBP1, encoding a novel human methanethiol oxidase, cause extraoral halitosis.

Pol A et al.

Nature Genetics, 2018

29255262 (PubMed )
Supplement: NIHMS74866-supplement-Supplementary_table_1.xlsx › EXAC_CFTR

The population genetics of human disease: The case of recessive, lethal mutations.

Amorim CEG et al.

Plos Genetics, 2017

28957316 (PubMed )
Supplement: pgen.1006915.s002.xlsx › Table_S2

Sweat chloride and immunoreactive trypsinogen in infants carrying two CFTR mutations and not affected by cystic fibrosis.

Castellani C et al.

Archives of Disease in Childhood, 2017

Newborn screening for cystic fibrosis in Alberta: Two years of experience.

Lilley M et al.

Paediatrics & Child Health, 2010

A new complex allele of the CFTR gene partially explains the variable phenotype of the L997F mutation.

Lucarelli M et al.

Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2010

A 10-year large-scale cystic fibrosis carrier screening in the Italian population.

Picci L et al.

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society, 2010

Sweat chloride testing in infants identified as heterozygote carriers by newborn screening.

Soultan ZN et al.

The Journal of Pediatrics, 2008

Age and origin of major Smith-Lemli-Opitz syndrome (SLOS) mutations in European populations.

Witsch-Baumgartner M et al.

Journal of Medical Genetics, 2008

Highly preferential association of NonF508del CF mutations with the M470 allele.

Ciminelli BM et al.

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society, 2007

Extensive sequencing of the CFTR gene: lessons learned from the first 157 patient samples.

McGinniss MJ et al.

Human Genetics, 2005

Gender-sensitive association of CFTR gene mutations and 5T allele emerging from a large survey on infertility.

Morea A et al.

Molecular Human Reproduction, 2005

Diagnostic testing by CFTR gene mutation analysis in a large group of Hispanics: novel mutations and assessment of a population-specific mutation spectrum.

Schrijver I et al.

The Journal of Molecular Diagnostics : Jmd, 2005

Cystic fibrosis in Greece: molecular diagnosis, haplotypes, prenatal diagnosis and carrier identification amongst high-risk individuals.

Kanavakis E et al.

Clinical Genetics, 2003

Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France.

Claustres M et al.

Human Mutation, 2000

Select a paper to view details
UCSC Genome Browser·Imprint·Privacy·Terms·Feedback·Email Updates·

Regarding the variants extracted from papers and shown text snippets from research papers, the following holds: "Some rights reserved. This work permits non-commercial use, distribution and reproduction in any medium, provided the original author and source are credited."